4D Molecular Therapeutics Inc
4D Molecular Therapeutics Inc logo
FDMT

4D Molecular Therapeutics Inc (FDMT)

$23.44.68%

Market is closed
– opens on 8 PM, 12 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$23.4
Day's Range
$25.3
$5.32
52-Week Range
$25.92
1 month return140.49%
3 month return156.02%
1 year return6.7%
5 year return42.22%

Company Information

4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP patients, 4D-110 is in a Phase 1 clinical trial for choroideremia patients and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease patients. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
Organization4D Molecular Therapeutics Inc
Employees140
CEODr. John F. Milligan Ph.D.
IndustryHealthcare

Analyst Recommendation

based on 3 analysts ratings

Buy
66%
Buy
33%
Hold
0%
Sell

Based on 3 Wall street analysts offering stock ratings for 4D Molecular Therapeutics Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 50.3%

Current

$23.4

Target

$35.17

Recommendation Trend

Based on 3 analyst

Current1M Ago3M Ago
Buy
2
8
9
Hold
1
3
2
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
758.0M
Book Value
$7.76
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.79
Wall Street Target Price
35.17

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
2.98
Enterprise Value
523.2M
Enterprise Value/Revenue
265.03
Enterprise Value/Ebitda
-5.09

Technicals

50 Day MA
13.08
200 Day MA
11.03

Institutional Holdings

Bvf Inc

12.37%

Viking Global Investors LP

12.16%

Deep Track Capital, LP

9.87%

BlackRock Inc

6.89%

Morgan Stanley - Brokerage Accounts

6.24%

ArrowMark Colorado Holdings, LLC (ArrowMark Partners)

4.72%

Discover more

Frequently Asked Questions

What is 4D Molecular Therapeutics Inc share price today?

Can Indians buy 4D Molecular Therapeutics Inc shares?

How can I buy 4D Molecular Therapeutics Inc shares from India?

Can Fractional shares of 4D Molecular Therapeutics Inc be purchased?

What are the documents required to start investing in 4D Molecular Therapeutics Inc stocks?

What are today’s High and Low prices of 4D Molecular Therapeutics Inc?

What are today’s traded volumes of 4D Molecular Therapeutics Inc?

What is today’s market capitalisation of 4D Molecular Therapeutics Inc?

What is the 52 Week High and Low Range of 4D Molecular Therapeutics Inc?

How much percentage 4D Molecular Therapeutics Inc is down from its 52 Week High?

How much percentage 4D Molecular Therapeutics Inc is up from its 52 Week low?

What are the historical returns of 4D Molecular Therapeutics Inc?

Who is the Chief Executive Officer (CEO) of 4D Molecular Therapeutics Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*